Washington, USA-based Seattle Genetics has announced data highlighting preclinical findings on two of its antibody-drug conjugate programs, SGN-35 and SGN-19A, as well as research advances with its proprietary ADC technology. The data were being presented at the European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research International Conference on Molecular Targets and Cancer Therapeutics being held in Geneva, Switzerland.
"Our ADC technology is gaining substantial momentum, demonstrated by the four empowered antibodies now in clinical trials between us and our collaborators, as well as progress with multiple preclinical programs," said Clay Siegall, chief executive of the firm. "Data presented on SGN-19A, our anti-CD19 ADC, suggest it may represent a promising addition to the treatment options for non-Hodgkin's lymphoma and other hematologic malignancies, including acute lymphoblastic leukemia. In addition, preclinical research with SGN-35 demonstrates its utility in a variety of Hodgkin's lymphoma settings, including in combination with upfront and salvage chemotherapy regimens, complementing our clinical data on its ability to induce objective responses as a single agent," he added.
Data summary
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze